Literature DB >> 29344580

Successful treatment with fingolimod of graft-versus-host disease of the central nervous system.

Jordan Gauthier1, Patrick Vermersch2,3, Paul Chauvet1, Pauline Varlet4, Valérie Coiteux1, Leonardo Magro1, Ibrahim Yakoub-Agha1,5.   

Abstract

Fingolimod could be efficient to treat GVHD of the central nervous system.Further research should explore the use of fingolimod and other sphingosine-1-phosphate receptor agonists to prevent or treat GVHD.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29344580      PMCID： PMC5761625          DOI： 10.1182/bloodadvances.2017011478

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  16 in total

1.  FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.

Authors:  Achilles Ntranos; Olivia Hall; Dionne P Robinson; Inna V Grishkan; Jason T Schott; Dominique M Tosi; Sabra L Klein; Peter A Calabresi; Anne R Gocke
Journal:  J Neuroimmunol       Date:  2014-03-11       Impact factor: 3.478

2.  Regulation of donor T cells in the tolerant rats to graft-versus-host disease by FTY720 following small bowel transplantation.

Authors:  J Song; T Ito; C Matsuda; M Tanemura; T Nishida; M Nozawa; Y Sawa
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

3.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

4.  Central nervous system graft-versus-host disease: report of two cases and literature review.

Authors:  R T Kamble; C-C Chang; S Sanchez; G Carrum
Journal:  Bone Marrow Transplant       Date:  2006-11-13       Impact factor: 5.483

5.  Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.

Authors:  Yong-Mi Kim; Teviah Sachs; Wannee Asavaroengchai; Roderick Bronson; Megan Sykes
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.

Authors:  Qiao Cheng; Shoubao Ma; Dandan Lin; Yu Mei; Huanle Gong; Lei Lei; Yuanyuan Chen; Ye Zhao; Bo Hu; Yan Wu; Xiao Yu; Lixiang Zhao; Haiyan Liu
Journal:  Cell Mol Immunol       Date:  2014-08-04       Impact factor: 11.530

7.  Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease.

Authors:  Anna Maria Delios; Marc Rosenblum; Ann A Jakubowski; Lisa M DeAngelis
Journal:  J Neurooncol       Date:  2012-08-23       Impact factor: 4.130

8.  FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.

Authors:  Doanh Le Huu; Takashi Matsushita; Guihua Jin; Yasuhito Hamaguchi; Minoru Hasegawa; Kazuhiko Takehara; Manabu Fujimoto
Journal:  Arthritis Rheum       Date:  2013-06

9.  Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).

Authors:  Patricia A Taylor; Michael J Ehrhardt; Christopher J Lees; Jakub Tolar; Brenda J Weigel; Angela Panoskaltsis-Mortari; Jonathan S Serody; Volker Brinkmann; Bruce R Blazar
Journal:  Blood       Date:  2007-07-02       Impact factor: 22.113

10.  Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.

Authors:  Nele Claes; Tessa Dhaeze; Judith Fraussen; Bieke Broux; Bart Van Wijmeersch; Piet Stinissen; Raymond Hupperts; Niels Hellings; Veerle Somers
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240
View more
  3 in total

Review 1.  Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.

Authors:  Qingxiao Song; Ubaydah Nasri; Ryotaro Nakamura; Paul J Martin; Defu Zeng
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

Review 2.  Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.

Authors:  Sina Naserian; Mathieu Leclerc; Sara Shamdani; Georges Uzan
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 3.  Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.

Authors:  Jacob Rozmus
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.